Extensively Drug Resistant-Tuberculosis, XDR-TB.
10.5124/jkma.2008.51.2.168
- Author:
Jae Seuk PARK
1
Author Information
1. Department of Internal Medicine, Dankook University College of Medicine, Korea. jspark@dankook.ac.kr
- Publication Type:Original Article
- Keywords:
Tuberculosis;
Multidrug-resistant;
Extensively drug-resistant
- MeSH:
Aminoglycosides;
Bacteria;
Compliance;
Extensively Drug-Resistant Tuberculosis;
Fluoroquinolones;
Humans;
Isoniazid;
Patient Compliance;
Rifampin;
Tuberculosis
- From:Journal of the Korean Medical Association
2008;51(2):168-175
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Multidrug-resistant tuberculosis(MDR-TB), resistant to at least the two main TB drugsisoniazid and rifampicin, has been a threat to TB control because the treatment requires more toxic drugs and longer period with poor treatment outcomes. Recently, more serious concerns have been raised about extensively drug resistant-tuberculosis (XDR-TB), which shows resistance to fluoroquinolones and aminoglycosides in addition to isoniazid and rifampicin. XDR-TB is a serious global health threat because the cure is very difficult as few sensitive anti-TB drugs remain. XDR-TB develops when first-and second-line anti-TB drugs are misused during the course of treatment, most commonly due to poor compliance of the patients to the treatment regimen. People with XDR-TB can pass the XDR-TB bacteria to other people. Thus, every effort should be made to prevent the development of XDR-TB by establishing an effective TB control program maximizing patient adherence to prescribed anti-TB regimen and minimizing contact of XDR-TB patients with other people to prevent the spread of XDR-TB.
